Source: Siyu MedTech
Reprint Requirements: Please indicate the source of the article at the beginning of the text, and it can be reprinted directly.
Shanghai, October 26, 2023 — Meeting with CIIE, advancing together with China. Today, Boston Scientific officially announced that it will appear at this year's CIIE with the theme "Innovating for Life, Advancing Together for a Shared Future," hoping to leverage the "strong magnetic field" of the CIIE spillover effect to further strengthen its connection with the local medical ecosystem, advance hand in hand with industry partners, resonate with the Chinese market, and move forward together towards a healthy future.
This year, Boston Scientific renews its "Four-Leaf Clover" commitment and is expected to showcase over 70 exhibits at the CIIE, covering areas such as healthy weight, cardiac health, peripheral vascular health, urological health, and cancer prevention and treatment. A number of "world's first" and "China's first exhibition" products that meet the diverse clinical needs of Chinese patients will make a significant appearance, with nearly half of the exhibits not yet available in mainland China. Meanwhile, as the medical innovation company with the most nominations for the Galien Award, known as the "Nobel Prize of the pharmaceutical industry," globally over the past five years from 2019 to present, Boston Scientific will exhibit nine award-winning or nominated products, demonstrating its profound innovative heritage. As an old friend of the CIIE, Boston Scientific will also highlight the fruitful achievements since participating in the CIIE and a series of new localization developments, firmly establishing itself as the most loyal partner in China's healthcare industry.Ms. Zhang Jun, President of Boston Scientific Greater China, stated: "The CIIE has demonstrated China's commitment to continuously expanding its opening up and sharing development opportunities. Over the past five years of accompanying the CIIE, Boston Scientific has seized the 'golden key' of CIIE opportunities, achieving new breakthroughs in localization year after year. These achievements have further strengthened our confidence and determination to deepen our presence in the Chinese market. In the future, we will continue to collaborate with partners from all sectors, benefiting Chinese patients and healthcare providers with cutting-edge medical innovations, and promoting the vigorous development of China’s healthcare industry."# Carry Forward the CIIE Effect, All Innovative Achievements on DisplayAt the CIIE, a grand event云集 with global cutting-edge technologies, this year, Boston Scientific will present three new achievements in the field of minimally invasive interventional precision treatment. Hoping to leverage the exposure effect of the CIIE, the company aims to help reduce the burden of disease treatment in China and improve the healthy life expectancy of residents. Focusing on the increasingly common issue of obesity, Boston Scientific will exhibit for the first time in China a globally pioneering, FDA-approved endoscopic weight management product featuring a single intragastric balloon—Orbera Intragastric Balloon*. The only device currently available that features active aspiration and perfusion functions, and simultaneously possesses the ability to address three types of lesions—calcification, plaque, and thrombus—through plaque removal in endovascular interventional therapy –Jetstream Atherectomy System*Will debut at this year's CIIE. The product was included in the "Green Channel" of the National Medical Products Administration's special review process for innovative medical devices in 2021. In addition, last year's star exhibit at the CIIE —ROTAPRO Rotational Atherectomy System*It will also have a pre-launch release at this CIIE, with the potential to become Boston Scientific's 6th innovative medical solution to transition from "exhibit to product."
From left to right: Orbera Intragastric Balloon*, Jetstream Atherectomy System*, ROTAPRO Rotational Atherectomy System*Focusing on the increasing prevalence of cardiovascular diseases among Chinese patients, Boston Scientific will showcase several innovative products at this year's CIIE. The company hopes to leverage the accelerating effect of the CIIE to expedite the process of benefiting a wide range of Chinese patients. AsThe world's first medical device company to provide a comprehensive solution integrating "ice," "fire," and "electricity" in the field of atrial fibrillation ablation., Boston Scientific will comprehensively showcase three products at the CIIE, including cryoablation, radiofrequency ablation, and pulsed electric field ablation.The World's First Approved Pulsed Field Ablation (PFA) System FARAPULSE*. As the latest cutting-edge product in Boston Scientific's comprehensive "ice," "fire," and "electricity" solution, this product will provide a "full-energy" solution for the atrial fibrillation ablation field in China, better meeting the diverse treatment needs of Chinese doctors and patients. Additionally, it received FDA approval in the United States just this September.WATCHMAN FLX Pro Left Atrial Appendage Closure Device*Will make its "China debut" at this year's CIIE, while also being exhibitedACURATE neo2 Transcatheter Implantable Heart Valve*Will also bring new hope to patients with severe calcific aortic stenosis.# Accelerating Localization Further to Realize "Exhibitors Becoming Investors"Since embarking on its CIIE journey in 2019, Boston Scientific has witnessed five years of the CIIE’s continuous improvement, and has also created a golden five years of deepening localization in China. With the spotlight of the CIIE, Boston Scientific has not only introduced innovative products...Achieved the "three-step" process of "import to domestic production and then to export", this year alsoAgainAchieve "Transforming Exhibitors into Investors"The upgrade. As localization deepens, Boston Scientific will showcase these new developments of "sharing China opportunities" on the CIIE stage, aiming to inject new momentum into the thriving innovation ecosystem of China's healthcare industry.Leveraging the Medical Device Registration Holder (MAH) system, the Polaris Intravascular Ultrasound System [1] received its local registration certificate in July 2022, enabling local production while supplying the global market. This achievement not only completed the transformation of an imported product showcased at the CIIE into one that is "imported, localized, and then exported," but also marked a crucial step for Boston Scientific in realizing its transition from "In China, For China" to "In China, For Global." The new generationAVVIGO+ Intravascular Ultrasound System*Developed with the participation of Boston Scientific's China team, its core V4 image acquisition host is entirely produced in China and will be prioritized for overseas markets, becoming another Boston Scientific product to achieve "In China, For Global." In September this year, the product officially received dual certification approval from the U.S. FDA and EU CE, and will make its first appearance in China at this year's CIIE.As a "repeat participant" and "regular attendee" of the CIIE, Boston Scientific has regarded the event as an excellent platform to tap into China's vast potential. This year, Boston Scientific once again welcomed new progress in local production with the identity of an "investor." In October 2023, Boston Scientific announced the establishment of its first production and manufacturing base in China in Shanghai, planning to locate it in the Life Blue Bay pharmaceutical specialty park in the Lingang Special Area. In the future, the medical devices produced at this base will mainly supply the Chinese market, using locally manufactured products to help improve the accessibility of cutting-edge medical technologies. Looking ahead, Boston Scientific will initiate a new chapter of synchronized development with China through a localization strategy covering all aspects of the industry chain, including trade, production, research and development, investment, and services.#About Boston Scientific
Boston Scientific Corporation is committed to innovation for life. We are dedicated to innovative medical solutions that improve the lives of patients worldwide. For over four decades, Boston Scientific has consistently led the global medical technology industry by delivering a wide range of high-performance medical solutions that meet the urgent treatment needs of many patients and reduce healthcare costs.
#About Boston Scientific Greater ChinaBoston Scientific set up its China headquarters in Shanghai in 1997 and currently has branches in Beijing, Guangzhou, Chengdu, Hong Kong, and Taipei. The company's core businesses cover cardiac intervention, structural heart disease, cardiac rhythm management, electrophysiology, endoscopic intervention, oncology intervention, peripheral intervention, urology, respiratory intervention, otolaryngology, and neuromodulation. Upholding the tradition of being an innovation leader, Boston Scientific is committed to becoming a respected medical technology company that meets the needs of doctors and patients, demonstrates innovative vitality, and provides high-quality medical products and services for prevention, diagnosis, and treatment.*The above products have not yet been launched in mainland China.*The above products have not yet been launched in mainland China.[1] NMPA Registration No. 20223060932, NMPA Registration No. 20223060933
Editor-in-Chief | Zhao Qing Reviewer | Yi He Typesetting | Miya
